Kidney Cancer Trials

Open

Name: IRB #R7027 Pilot, Immunologic effects of RT. Pre and post-treatment biopsies to look at T-regs.
Target Population: Melanoma or RCC.
Inclusion/Exclusion: Symptomatic cutaneous or subcutaneous metastases planned to get RT.
Status: open for recruitment
Contact Info: 212-305-0114

 

Name: IRB #R3743 Phase II HCRNA GU 16-260 (Hoosier). 120 ccRCC and 40 nccRCC --> Part A nivo monotherapy; Part B nivo/ipi on progression with nivo.
Target Population: mRCC, first line.
Inclusion/Exclusion: Part A: at least one site of measurable disease; mandatory archival tissue; controlled brain mets ok; Part B prior nivo is allowed; no surgery or RT within 14 days of start.
Status: open for recruitment
Contact Info: 212-305-0114

 

Name: IRB #R6272 Phase Ib/II, IL8+/- nivo. BMS-986253 + nivo q4 weeks.
Target Population: PD1/L1 treated RCC.
Inclusion/Exclusion: PD1/L1 treated RCC, must have had (been intolerant or refused) 1 prior VEGF TKI; PD1/PDL1 treated UC, must have received (been intolerant or refused) chemo for mUC.
Status: open for recruitment
Contact Info: 212-305-0114

 

Name: IRB #R3867 Phase I, IL8+/- nivo. RGX-104 + nivo dose escalation.
Target Population: Progression on therapy.
Inclusion/Exclusion: RCC: ≤2 prior regimens with VEGF inhibitors and ≤1 prior check point inhibitor for metastatic disease; UC: check point treated ok, ≤2 prior regimens for UC; variant histology ok but predominant histology should be UC.
Status: open for recruitment
Contact Info: 212-305-0114